InvestSMART

Arovella Therapeutics Limited (ASX:ALA)

ALERT: Price-sensitive ASX Announcement for ALA
Current share price for ALA : $0.069 -0.019 (-21.59%)+
Announcement
Release
23 Sep 2025 9:10AM
Price at Release
$0.088
Full Release
download
Summary
Arovella Therapeutics Limited (ASX: ALA) announced the receipt of a $3.21 million R&D tax incentive refund for the financial year 2025. This refund strengthens the company's financial position as it prepares to initiate first-in-human clinical trials for its leading asset, ALA-101, which targets CD19-positive lymphoma and leukaemia. The CEO, Dr. Michael Baker, highlighted the company's plan to lodge an IND application with the FDA within the year, aiming to commence clinical trials for ALA-101. The Australian Government’s R&D Tax Incentive program provides cash refunds for a significant percentage of eligible R&D expenditures, supporting companies in their development activities.
Key Points
  • Arovella Therapeutics Limited received a $3.21 million R&D tax rebate.
  • The rebate supports the development of Arovella's lead product, ALA-101, targeting CD19-positive lymphoma and leukaemia.
  • Arovella plans to lodge an IND application to the FDA for ALA-101 this calendar year.
  • The R&D Tax Incentive provides cash refunds for eligible R&D expenditures.
  • ALA-101 is being developed as an allogeneic cell therapy using iNKT cell technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.